FDA approves Bosulif (bosutinib) for pediatric Ph+ CP-CML – Pfizer
The FDA has approved bosutinib (Bosulif) for the treatment of pediatric patients 1 year of age and older with Philadelphia chromosome (Ph)–positive, chronic-phase chronic myelogenous leukemia (CP-CML) that… read more.